Jonathan D Licht

List of Publications by Year
in descending order

331 papers	24,757 citations	9264 74 h-index	7518 151 g-index
342 all docs	342 docs citations	342 times ranked	31064 citing authors

#	Article	IF	Citations
1	PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by <i>NSD2</i> Mutation in Pediatric Acute Lymphoblastic Leukemia. Cancer Discovery, 2022, 12, 186-203.	9.4	17
2	DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks. Clinical Cancer Research, 2022, 28, 756-769.	7.0	9
3	Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like Phenotype. Molecular Cancer Therapeutics, 2022, 21, 511-521.	4.1	3
4	HDAC11 activity contributes to MEK inhibitor escape in uveal melanoma. Cancer Gene Therapy, 2022, 29, 1840-1846.	4.6	3
5	Analysis of Biological Aging and Risks of All-Cause and Cardiovascular Diseaseâ€“Specific Death in Cancer Survivors. JAMA Network Open, 2022, 5, e2218183.	5.9	7
6	The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma. Leukemia, 2021, 35, 796-808.	7.2	19
7	Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture. Nature, 2021, 589, 299-305.	27.8	155
8	Separation and Characterization of Endogenous Nucleosomes by Native Capillary Zone Electrophoresisâ€“Top-Down Mass Spectrometry. Analytical Chemistry, 2021, 93, 5151-5160.	6.5	16
9	Leveraging epigenetics to enhance the efficacy of immunotherapy. Clinical Epigenetics, 2021, 13, 115.	4.1	24
10	Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition. Molecular Cell, 2021, 81, 2183-2200.e13.	9.7	59
11	Combined epigenetic and metabolic treatments overcome differentiation blockade in acute myeloid leukemia. IScience, 2021, 24, 102651.	4.1	4
12	Targeting epigenetic mechanisms to overcome venetoclax resistance. Biochimica Et Biophysica Acta - Molecular Cell Research, 2021, 1868, 119047.	4.1	7
13	The role of sex and rurality in cancer fatalistic beliefs and cancer screening utilization in Florida. Cancer Medicine, 2021, 10, 6048-6057.	2.8	5
14	Functional Genomic and Immune Response Characterization of PTEN Loss: Therapeutic Implications for Myeloma. Blood, 2021, 138, 1612-1612.	1.4	0
15	Functional CRISPR Screening Identifies Ptprg As a Driver of Migration and Adhesion in NSD2-E1099K ALL. Blood, 2021, 138, 1149-1149.	1.4	0
16	Dysregulation of Epigenetic Landscape Uncovered the Mechanisms Underlying the Relapse of Pediatric Acute Lymphoblastic Leukemia with NSD2 Mutation. Blood, 2021, 138, 3297-3297.	1.4	0
17	Adenylate Kinase 2 Is a Selective Multiple Myeloma Cell Dependency That Is Preferentially Essential in NSD2-Overexpressing Cells. Blood, 2021, 138, 1586-1586.	1.4	0
18	Widespread microRNA degradation elements in target mRNAs can assist the encoded proteins. Genes and Development, 2021, 35, 1595-1609.	5.9	33

#	Article	IF	Citations
19	Functional Oncogenomic and Immune Response Landscape for Genes Recurrently Mutated in Myeloma. Blood, 2021, 138, 1589-1589.	1.4	0
20	Decitabine limits escape from MEK inhibition in uveal melanoma. Pigment Cell and Melanoma Research, 2020, 33, 507-514.	3.3	17
21	Histone H3 G34 Tail Mutations in Cancer: Actions in <i>Cis</i> and <i>Trans</i> to Alter Chromatin and Gene Expression. Cancer Discovery, 2020, 10, 1794-1796.	9.4	1
22	Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma. Genome Research, 2020, 30, 1217-1227.	5.5	35
23	High-throughput gene screen reveals modulators of nuclear shape. Molecular Biology of the Cell, 2020, 31, 1392-1402.	2.1	29
24	Oncogenesis by E2A-PBX1 in ALL: RUNX and more. Blood, 2020, 136, 3-4.	1.4	10
25	FOXM1 regulates leukemia stem cell quiescence and survival in MLL-rearranged AML. Nature Communications, 2020, 11, 928.	12.8	54
26	Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma. Cancer Letters, 2020, 475, 99-108.	7.2	22
27	KDM6A Controls Genes Modulating Immune Surveillance in Multiple Myeloma. Blood, 2020, 136, 14-14.	1.4	1
28	Interactions with a "Humanized" Mesenchymal Bone Marrow Stromal Niche In Vivo Modify the Patterns of Essential Genes for Myeloma Cells: Therapeutic Implications. Blood, 2020, 136, 40-40.	1.4	0
29	Functional Genomic Characterization of Endoplasmic Reticulum-Associated Dependencies in Multiple Myeloma - Biologic and Therapeutic Implications. Blood, 2020, 136, 3-4.	1.4	0
30	NSD2-E1099K Mutation Leads to Glucocorticoid-Resistant B Cell Lymphocytic Leukemia in Mice. Blood, 2020, 136, 3-4.	1.4	0
31	<i>POU2AF1</i> As a Master Regulator of Oncogenic Transcription Factor Networks in Myeloma. Blood, 2020, 136, 18-19.	1.4	4
32	Use of Olfactory Receptor Genes As Controls for Genome-Scale CRISPR Functional Genomic Studies to Define Treatment Resistance Mechanisms. Blood, 2020, 136, 36-36.	1.4	2
33	Adenylate Kinase 2 Is a Selective Dependency in NSD2-High Multiple Myeloma. Blood, 2020, 136, 31-31.	1.4	0
34	Sprouty1 Controls Genitourinary Development via its N-Terminal Tyrosine. Journal of the American Society of Nephrology: JASN, 2019, 30, 1398-1411.	6.1	5
35	A Mutation in Histone H2B Represents a New Class of Oncogenic Driver. Cancer Discovery, 2019, 9, 1438-1451.	9.4	65
36	Defining the NSD2 interactome: PARP1 PARylation reduces NSD2 histone methyltransferase activity and impedes chromatin binding. Journal of Biological Chemistry, 2019, 294, 12459-12471.	3.4	16

#	Article	IF	Citations
37	MYB-activated models for testing therapeutic agents in adenoid cystic carcinoma. Oral Oncology, 2019, 98, 147-155.	1.5	18
38	Molecular markers of myeloma cell sensitivity vs. resistance to heterobifunctional degraders of oncoproteins: therapeutic implications.. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e134.	0.4	1
39	HDAC Inhibition Enhances the <i>In Vivo</i> Efficacy of MEK Inhibitor Therapy in Uveal Melanoma. Clinical Cancer Research, 2019, 25, 5686-5701.	7.0	75
40	HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy. Cancer Research, 2019, 79, 2947-2961.	0.9	59
41	CRISPR studies identify genes preferentially essential for myeloma cells vs. other neoplasias: implications for future therapies selective against MM. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e48-e49.	0.4	0
42	CRISPR-based functional genomics landscape of genes recurrently mutated in MM. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e77-e78.	0.4	0
43	An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia. Oncogene, 2019, 38, 671-686.	5.9	39
44	Inhibition of cardiomyocyte Sprouty1 protects from cardiac ischemiaâ€“reperfusion injury. Basic Research in Cardiology, 2019, 114, 7.	5.9	18
45	Systematic Characterization of Genes Representing Preferential Molecular Vulnerabilities for Myeloma Cells Compared to Other Neoplasias - Implications for the Biology and Therapeutic Targeting of Myeloma. Blood, 2019, 134, 4407-4407.	1.4	4
46	Abstract 1922: MYB mimic peptides targeting human and murine MYB-NFIB positive tumor cells. , 2019, , .		0
47	Abstract 378: HDAC inhibition enhances MEK antagonist therapy in uveal melanoma through combined blockade of YAP, AKT and RTK signaling. , 2019, , .		0
48	Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins. Blood, 2019, 134, 318-318.	1.4	0
49	Identification of Genetic Vulnerabilities and Synthetic-Lethal Targets in NSD2-High Multiple Myeloma. Blood, 2019, 134, 3757-3757.	1.4	1
50	DNMT3A with Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks. Blood, 2019, 134, 535-535.	1.4	1
51	A Gain of Function Mutation in the NSD2 Histone Methyltransferase Drives Glucocorticoid Resistance Via Blocking Receptor Auto-Induction and BIM/Bmf Expression in ALL. Blood, 2019, 134, 3758-3758.	1.4	1
52	Abstract 3800: HDAC8 regulates plasticity and escape from therapy in BRAF mutant melanoma. , 2019, , .		0
53	A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer. Oncogene, 2018, 37, 1911-1925.	5.9	102
54	The nucleus is irreversibly shaped by motion of cell boundaries in cancer and nonâ€cancer cells. Journal of Cellular Physiology, 2018, 233, 1446-1454.	4.1	49

#	Article	IF	Citations
55	Targeting Epigenetics in Cancer. Annual Review of Pharmacology and Toxicology, 2018, 58, 187-207.	9.4	185
56	Loss of Spry1 attenuates vascular smooth muscle proliferation by impairing mitogenâ€mediated changes in cell cycle regulatory circuits. Journal of Cellular Biochemistry, 2018, 119, 3267-3279.	2.6	11
57	HOTTIP lncRNA Promotes Hematopoietic Stem Cell Self-Renewal Leading to AML-Like Disease in Mice. SSRN Electronic Journal, 2018, , .	0.4	5
58	Epigenetic Therapy. , 2018, , 1-1.		2
59	Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator. Cell Reports, 2018, 25, 2808-2820.e4.	6.4	201
60	Targeting EZH2 in Multiple Myelomaâ€"Multifaceted Anti-Tumor Activity. Epigenomes, 2018, 2, 16.	1.8	18
61	USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism. Blood, 2018, 132, 423-434.	1.4	49
62	CTCF boundary remodels chromatin domain and drives aberrant HOX gene transcription in acute myeloid leukemia. Blood, 2018, 132, 837-848.	1.4	56
63	A Gain of Function Mutation in the NSD2 Histone Methyltransferase Drives Glucocorticoid Resistance of Acute Lymphoblastic Leukemia. Blood, 2018, 132, 653-653.	1.4	7
64	Abstract 343: Targeting DNA replication as a therapeutic strategy for acute myeloid leukemia with DNMT3A mutations. , 2018, , .		0
65	Functional Genomic Landscape of Genes with Recurrent Mutations in Multiple Myeloma. Blood, 2018, 132, 189-189.	1.4	2
66	Epigenetic Regulation and Therapeutic Targeting in Myeloma. Blood, 2018, 132, SCI-37-SCI-37.	1.4	1
67	Cells with DNMT3A Mutations Are More Sensitive to Cytarabine-Induced DNA Damage. Blood, 2018, 132, 2643-2643.	1.4	3
68	Dissecting the Epigenetic Landscape of Smoldering, Newly Diagnosed and Relapsed Multiple Myeloma Revealed IRAK3 As a Marker of Disease Progression. Blood, 2018, 132, 3896-3896.	1.4	1
69	CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins: Implications for Novel Therapeutics across Diverse Neoplasias. Blood, 2018, 132, 1367-1367.	1.4	0
70	Loss of KDM6A/UTX Accelerate the Development of Multiple Myeloma. Blood, 2018, 132, 1004-1004.	1.4	1
71	DISORDERED HISTONE METHYLATION IN HEMATOLOGICAL MALIGNANCIES THE CASE OF UTX/KDM6A. Transactions of the American Clinical and Climatological Association, 2018, 129, 24-36.	0.5	1
72	Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors. Leukemia and Lymphoma, 2017, 58, 218-221.	1.3	1

#	Article	IF	Citations
73	The Role of Nuclear Receptorâ€"Binding SET Domain Family Histone Lysine Methyltransferases in Cancer. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a026708.	6.2	122
74	Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma. Current Opinion in Hematology, 2017, 24, 336-344.	2.5	36
75	Sabotaging of the oxidative stress response by an oncogenic noncoding RNA. FASEB Journal, 2017, 31, 482-490.	0.5	9
76	Histone H1 and Chromosomal Protein HMGN2 Regulate Prolactin-induced STAT5 Transcription Factor Recruitment and Function in Breast Cancer Cells. Journal of Biological Chemistry, 2017, 292, 2237-2254.	3.4	26
77	UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition. Cell Reports, 2017, 21, 628-640.	6.4	106
78	SETD2: a complex role in blood malignancy. Blood, 2017, 130, 2576-2578.	1.4	20
79	FQI1: a transcription-methylation switch for cancer. Oncotarget, 2017, 8, 12536-12537.	1.8	0
80	Loss of Mll3 Catalytic Function Promotes Aberrant Myelopoiesis. PLoS ONE, 2016, 11, e0162515.	2.5	11
81	MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents. Oncogene, 2016, 35, 5905-5915.	5.9	74
82	H3K27 Methylation. Advances in Cancer Research, 2016, 131, 59-95.	5.0	48
83	EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis. Cancer Cell, 2016, 30, 197-213.	16.8	200
84	Unabridged Analysis of Human Histone H3 by Differential Top-Down Mass Spectrometry Reveals Hypermethylated Proteoforms from MMSET/NSD2 Overexpression. Molecular and Cellular Proteomics, 2016, 15, 776-790.	3.8	56
85	Post transcriptional control of the epigenetic stem cell regulator PLZF by sirtuin and HDAC deacetylases. Epigenetics and Chromatin, 2015, 8, 38.	3.9	11
86	GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1. Scientific Reports, 2015, 5, 9489.	3.3	77
87	Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation. Leukemia and Lymphoma, 2015, 56, 2895-2901.	1.3	28
88	WHSC1 Promotes Oncogenesis through Regulation of NIMA-Related Kinase-7 in Squamous Cell Carcinoma of the Head and Neck. Molecular Cancer Research, 2015, 13, 293-304.	3.4	82
89	DNA Methylation Inhibitors in Cancer Therapy: The Immunity Dimension. Cell, 2015, 162, 938-939.	28.9	55
90	Deregulation of the Ras-Erk Signaling Axis Modulates the Enhancer Landscape. Cell Reports, 2015, 12, 1300-1313.	6.4	37

#	Article	IF	Citations
91	High Throughput Screening Identifies Potential Inhibitors of WHSC1/MMSET, a Histone Methyltransferase Oncoprotein in Multiple Myeloma and Acute Lymphocytic Leukemia. Blood, 2015, 126, 3251-3251.	1.4	1
92	Abstract IA26: Aberrant histone methylation in multiple myeloma.. , 2015, , .		0
93	Abstract B32: Loss of the histone demethylase UTX alters the gene expression prolife and contributes to the malignant phenotype of multiple myeloma cells.. , 2015, , .		0
94	Abstract PR09: Extracellular stiffness cues drive spatial reorganization of the genome to globally constrain RNA abundance. , 2015, , .		1
95	Allele-Specific Crispr Targeting Reveals Epigenetic and Phenotypic Effects of a MMSET Gain of Function Mutation Found in Relapsed Acute Lymphoblastic Leukemia. Blood, 2015, 126, 437-437.	1.4	3
96	Single-cell nucleosome mapping reveals the molecular basis of gene expression heterogeneity. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E2462-71.	7.1	96
97	Histone Methyltransferase MMSET/NSD2 Alters EZH2 Binding and Reprograms the Myeloma Epigenome through Global and Focal Changes in H3K36 and H3K27 Methylation. PLoS Genetics, 2014, 10, e1004566.	3.5	178
98	Promyelocytic Leukemia Zinc Finger-Retinoic Acid Receptor Î± (PLZF-RARÎ±), an Oncogenic Transcriptional Repressor of Cyclin-dependent Kinase Inhibitor 1A (p21WAF/CDKN1A) and Tumor Protein p53 (TP53) Genes. Journal of Biological Chemistry, 2014, 289, 18641-18656.	3.4	19
99	Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies. Leukemia, 2014, 28, 198-201.	7.2	122
100	DNA Hydroxymethylation Profiling Reveals that WT1 Mutations Result in Loss of TET2 Function in Acute Myeloid Leukemia. Cell Reports, 2014, 9, 1841-1855.	6.4	237
101	From Anecdote to Targeted Therapy: The Curious Case of Thalidomide in Multiple Myeloma. Cancer Cell, 2014, 25, 9-11.	16.8	26
102	Molecular Pathways: Deregulation of Histone H3 Lysine 27 Methylation in Cancerâ€"Different Paths, Same Destination. Clinical Cancer Research, 2014, 20, 5001-5008.	7.0	75
103	Loss of the Histone Demethylase UTX Contributes to Multiple Myeloma and Sensitizes Cells to EZH2 Inhibitors. Blood, 2014, 124, 611-611.	1.4	7
104	Identification of an Epithelial-to-Mesenchymal Transition (EMT)-like Programme in t(4;14)-Positive Multiple Myeloma Reveals Novel Targets for Therapeutic Intervention. Blood, 2014, 124, 647-647.	1.4	1
105	Abstract SY09-03: How deregulation of histone methyltransferases drive malignant transformation of B-cells. , 2014, , .		0
106	Abstract 2344: 3D extracellular stiffness cues drive localized changes in gene expression. , 2014, , .		0
107	Abstract 5538: Development of HDACi resistance in DLBCL leads to a switch in subtype towards a more differentiated B-cell and is associated with increased sensitivity to proteasome inhibition. , 2014, , .		0
108	Spry1 and Spry2 are necessary for eyelid closure. Developmental Biology, 2013, 383, 227-238.	2.0	21

#	Article	IF	Citations
109	miR-433 is aberrantly expressed in myeloproliferative neoplasms and suppresses hematopoietic cell growth and differentiation. Leukemia, 2013, 27, 344-352.	7.2	51
110	MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC. Leukemia, 2013, 27, 686-694.	7.2	73
111	Epigenetic therapy of hematological malignancies: where are we now?. Therapeutic Advances in Hematology, 2013, 4, 81-91.	2.5	23
112	Mitochondria Are Required for Antigen-Specific T Cell Activation through Reactive Oxygen Species Signaling. Immunity, 2013, 38, 225-236.	14.3	981
113	The Proto-oncometabolite Fumarate Binds Glutathione to Amplify ROS-Dependent Signaling. Molecular Cell, 2013, 51, 236-248.	9.7	244
114	EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation. Cancer Cell, 2013, 23, 677-692.	16.8	706
115	ALS Untangled No. 20: The Deanna Protocol. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 319-323.	1.7	19
116	Essential Role for the Mnk Pathway in the Inhibitory Effects of Type I Interferons on Myeloproliferative Neoplasm (MPN) Precursors. Journal of Biological Chemistry, 2013, 288, 23814-23822.	3.4	16
117	The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelialâ€"mesenchymal transition and invasive properties of prostate cancer. Oncogene, 2013, 32, 2882-2890.	5.9	130
118	A physical sciences network characterization of non-tumorigenic and metastatic cells. Scientific Reports, 2013, 3, 1449.	3.3	146
119	Ponatinibâ€"A Step Forward in Overcoming Resistance in Chronic Myeloid Leukemia. Clinical Cancer Research, 2013, 19, 5828-5834.	7.0	31
120	Expression of Leukemia-Associated Fusion Proteins Increases Sensitivity to Histone Deacetylase Inhibitorâ€"Induced DNA Damage and Apoptosis. Molecular Cancer Therapeutics, 2013, 12, 1591-1604.	4.1	21
121	EZH2 and BCL6 Cooperate To Create The Germinal Center B-Cell Phenotype and Induce Lymphomas Through Formation and Repression Of Bivalent Chromatin Domains. Blood, 2013, 122, 1-1.	1.4	23
122	MMSET/WHSC1 Enhances DNA Damage Repair Leading To An Increase In Resistance To Chemotherapeutic Agents. Blood, 2013, 122, 808-808.	1.4	0
123	Sprouty Proteins Are Negative Regulators of Interferon (IFN) Signaling and IFN-inducible Biological Responses. Journal of Biological Chemistry, 2012, 287, 42352-42360.	3.4	36
124	Total kinetic analysis reveals how combinatorial methylation patterns are established on lysines 27 and 36 of histone H3. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 13549-13554.	7.1	129
125	Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nature Medicine, 2012, 18, 1118-1122.	30.7	162
126	G Protein-regulated Inducer of Neurite Outgrowth (GRIN) Modulates Sprouty Protein Repression of Mitogen-activated Protein Kinase (MAPK) Activation by Growth Factor Stimulation. Journal of Biological Chemistry, 2012, 287, 13674-13685.	3.4	15

#	Article	IF	Citations
127	Spry1 as a novel regulator of erythropoiesis, EPO/EPOR target, and suppressor of JAK2. Blood, 2012, 119, 5522-5531.	1.4	11
128	miR-27b controls venous specification and tip cell fate. Blood, 2012, 119, 2679-2687.	1.4	107
129	New Strategies in Acute Myeloid Leukemia: Redefining Prognostic Markers to Guide Therapy. Clinical Cancer Research, 2012, 18, 5163-5171.	7.0	12
130	Emerging Epigenetic Targets and Therapies in Cancer Medicine. Cancer Discovery, 2012, 2, 405-413.	9.4	106
131	Regulation of CD4+ and CD8+ Effector Responses by Sprouty-1. PLoS ONE, 2012, 7, e49801.	2.5	16
132	Abstract 1046: The histone methyl transferase MMSET/WHSC1 promotes an epithelial-mesenchymal transition and invasive properties of prostate cancer. , 2012, , .		0
133	Abstract 2165: Sprouty loss leads to aberrant regulation of receptor tyrosine kinase signaling pathways and accelerates mammary tumorigenesis. , 2012, , .		0
134	Aberrant Histone Methylation in Myeloma: What Are the Rules?. Blood, 2012, 120, SCI-5-SCI-5.	1.4	0
135	MMSET Dysregulates Gene Expression in Myeloma Through Global and Focal Changes in H3K36 and H3K27 Methylation. Blood, 2012, 120, 523-523.	1.4	1
136	Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms. Blood Cancer Journal, 2011, 1, e40-e40.	6.2	33
137	Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium. Blood Cancer Journal, 2011, 1, e7-e7.	6.2	13
138	<i>Spry1</i>and<i>Spry2</i>Are Necessary for Lens Vesicle Separation and Corneal Differentiation. , 2011, 52, 6887.		38
139	The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood, 2011, 117, 211-220.	1.4	300
140	MEK and MAF in myeloma therapy. Blood, 2011, 117, 2300-2302.	1.4	10
141	DNMT3A mutations in acute myeloid leukemia. Nature Genetics, 2011, 43, 289-290.	21.4	56
142	Functional characterization of Wilms tumor-suppressor WTX and tumor-associated mutants. Oncogene, 2011, 30, 832-842.	5.9	11
143	Abstract 2136: Expression of fusion proteins in acute myeloid leukemia cells increases sensitivity to histone deacetylase inhibitors. , 2011, , .		0
144	MMSET Contributes to Multiple Myeloma Oncogenesis Through Induction of Global Epigenetic Changes and Alteration of the DNA Damage Response,. Blood, 2011, 118, 3475-3475.	1.4	0

#	Article	IF	Citations
145	MMSET Stimulates Myeloma Cell Growth Through MicroRNA-Mediated Modulation of c-MYC. Blood, 2011, 118, 469-469.	1.4	0
146	Transcriptome analyses based on genetic screens for Pax3 myogenic targets in the mouse embryo. BMC Genomics, 2010, 11, 696.	2.8	41
147	Leukemic IDH1 and IDH2 Mutations Result inÂa Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation. Cancer Cell, 2010, 18, 553-567.	16.8	2,328
148	Partners in Crime: Genes within an Amplicon Collude to Globally Deregulate Chromatin in Lymphoma. Cancer Cell, 2010, 18, 539-541.	16.8	4
149	Deregulation of H3K27 methylation in cancer. Nature Genetics, 2010, 42, 100-101.	21.4	97
150	Transcriptional Profiling of Polycythemia Vera Identifies Gene Expression Patterns Both Dependent and Independent from the Action of JAK2V617F. Clinical Cancer Research, 2010, 16, 4339-4352.	7.0	31
151	Sprouty Proteins Inhibit Receptor-mediated Activation of Phosphatidylinositol-specific Phospholipase C. Molecular Biology of the Cell, 2010, 21, 3487-3496.	2.1	45
152	Kidney Development in the Absence of Gdnf and Spry1 Requires Fgf10. PLoS Genetics, 2010, 6, e1000809.	3.5	139
153	Sprouty1 Regulates Reversible Quiescence of a Self-Renewing Adult Muscle Stem Cell Pool during Regeneration. Cell Stem Cell, 2010, 6, 117-129.	11.1	275
154	HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype. Journal of Clinical Investigation, 2010, 120, 1535-1550.	8.2	98
155	Abstract 1126: Gene expression profiling reveals that WT1 and WTX control cell growth through similar gene networks but different specific genes. , 2010, , .		0
156	Mir-9 Is Aberrantly Expressed In MPN Patients and Accelerates Erythropoietic Cell Growth and Differentiation. Blood, 2010, 116, 1983-1983.	1.4	0
157	An integrated genome screen identifies the Wnt signaling pathway as a major target of WT1. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 11154-11159.	7.1	68
158	PLZF is a regulator of homeostatic and cytokine-induced myeloid development. Genes and Development, 2009, 23, 2076-2087.	5.9	87
159	Acute Promyelocytic Leukemia â€" Weapons of Mass Differentiation. New England Journal of Medicine, 2009, 360, 928-930.	27.0	46
160	Promyelocytic Leukemia Zinc Finger Protein Regulates Interferon-Mediated Innate Immunity. Immunity, 2009, 30, 802-816.	14.3	88
161	Ret-Dependent Cell Rearrangements in the Wolffian Duct Epithelium Initiate Ureteric Bud Morphogenesis. Developmental Cell, 2009, 17, 199-209.	7.0	193
162	Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood, 2009, 114, 2764-2773.	1.4	259

#	Article	IF	Citations
163	Survivin is not required for the endomitotic cell cycle of megakaryocytes. Blood, 2009, 114, 153-156.	1.4	20
164	MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood, 2009, 114, 3448-3458.	1.4	292
165	Comprehensive genomic screens identify a role for PLZF-RARÎ± as a positive regulator of cell proliferation via direct regulation of c-MYC. Blood, 2009, 114, 5499-5511.	1.4	53
166	Spry1 Plays Selective Hematopoietic Roles as An Erythropoietin - Modulated Positive Regulator of Erythropoiesis.. Blood, 2009, 114, 777-777.	1.4	0
167	The MMSET Histone Methyl Transferase Alters Chromatin Structure and Gene Expression in t(4;14) Multiple Myeloma Cells.. Blood, 2009, 114, 675-675.	1.4	0
168	Specific MicroRNA Deregulated in Myleoproliferative Neoplasm Are Regulated by JAK2V617F and May Contribute to Aberrant Hematopoiesis.. Blood, 2009, 114, 965-965.	1.4	15
169	Abstract A189: Expression of fusion proteins in acute myeloid leukemia cells increases sensitivity to histone deacetylase inhibitors. , 2009, , .		0
170	MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature, 2008, 456, 980-984.	27.8	2,111
171	ATF-2 controls transcription of Maspin and GADD45Î± genes independently from p53 to suppress mammary tumors. Oncogene, 2008, 27, 1045-1054.	5.9	77
172	Retinoblastoma protein and the leukemia-associated PLZF transcription factor interact to repress target gene promoters. Oncogene, 2008, 27, 5260-5266.	5.9	10
173	A Pathologic Link between Wilms Tumor Suppressor Gene, WT1, and IFI16. Neoplasia, 2008, 10, 69-IN29.	5.3	23
174	WT1 Induction of Mitogen-Activated Protein Kinase Phosphatase 3 Represents a Novel Mechanism of Growth Suppression. Molecular Cancer Research, 2008, 6, 1225-1231.	3.4	17
175	The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood, 2008, 111, 3145-3154.	1.4	176
176	Reversible disruption of BCL6 repression complexes by CD40 signaling in normal and malignant B cells. Blood, 2008, 112, 644-651.	1.4	40
177	New molecular concepts and targets in acute myeloid leukemia. Current Opinion in Hematology, 2008, 15, 82-87.	2.5	28
178	Integrative Analysis of Genomic Aberration and Gene Expression Suggests That MPD with Loss of Heterozygosity or Gain of Chromosome 9 Represents a Distinct Entity. Blood, 2008, 112, 3735-3735.	1.4	5
179	Comprehensive Genomic Screens Reveal Multiple Modes of Action of the PLZF-RAR-Î± Oncoprotein. Blood, 2008, 112, 686-686.	1.4	0
180	PLZF-RARÎ± Utilizes the Histone Methyl Transferase G9a/GLP and the Histone Demethylase LSD1 to Repress RARÎ± Target Genes and Block Myeloid Differentiation. Blood, 2008, 112, 198-198.	1.4	0

#	Article	IF	Citations
181	NFIB: A Gene Consistently Upregulated in MPD and Frequently Co-Amplified with JAK2V617F Augments Growth of Erythropoietin Dependent Cells. Blood, 2008, 112, 3727-3727.	1.4	0
182	Genome-Wide Chromatin Immunopreciptiation and Gene Expression Analysis Indicates That MMSET Is a Transcriptional Repressor in Vivo. Blood, 2008, 112, 627-627.	1.4	0
183	What unleashes aberrant gene regulation in acute promyelocytic leukemia?. Blood, 2007, 109, 857-857.	1.4	0
184	Molecular characterization of acute myeloid leukemia and its impact on treatment. Current Opinion in Oncology, 2007, 19, 635-649.	2.4	24
185	Physical and Functional Interactions of Human Endogenous Retrovirus Proteins Np9 and Rec with the Promyelocytic Leukemia Zinc Finger Protein. Journal of Virology, 2007, 81, 5607-5616.	3.4	121
186	Epigenetic regulation of normal and malignant hematopoiesis. Oncogene, 2007, 26, 6697-6714.	5.9	127
187	Sprouty2 inhibits BDNF-induced signaling and modulates neuronal differentiation and survival. Cell Death and Differentiation, 2007, 14, 1802-1812.	11.2	65
188	Chromatin Modulation by Oncogenic Transcription Factors: New Complexity, New Therapeutic Targets. Cancer Cell, 2007, 11, 475-478.	16.8	26
189	The PLZF Gene of t(11;17)-Associated APL. , 2007, 313, 31-48.		24
190	HOX deregulation in acute myeloid leukemia. Journal of Clinical Investigation, 2007, 117, 865-868.	8.2	66
191	A Comprehensive Genomic Approach Using Gain of Function Cell Models, Patient Specimens and ChIP-on-CHIP Technologies Identifies PLZF-RARÎ± Target Genes with Potential Roles in t(11;17) Associated APL.. Blood, 2007, 110, 3168-3168.	1.4	6
192	Myelodysplastic Syndrome (MDS) Displays Profound and Functionally Significant Epigenetic Deregulation Compared to Acute Myeloid Leukemia (AML) and Normal Bone Marrow Cells.. Blood, 2007, 110, 345-345.	1.4	2
193	Retinoblastoma Protein and the Leukemia-Associated PLZF Transcription Factor Interact To Repress Target Gene Promoters.. Blood, 2007, 110, 1240-1240.	1.4	0
194	Computational Identification of Ftz/Ftz-F1 downstream target genes. Developmental Biology, 2006, 299, 78-90.	2.0	19
195	Branching morphogenesis of the ureteric epithelium during kidney development is coordinated by the opposing functions of GDNF and Sprouty1. Developmental Biology, 2006, 299, 466-477.	2.0	141
196	Reconstructing a disease: What essential features of the retinoic acid receptor fusion oncoproteins generate acute promyelocytic leukemia?. Cancer Cell, 2006, 9, 73-74.	16.8	76
197	Sprouty proteins: multifaceted negative-feedback regulators of receptor tyrosine kinase signaling. Trends in Cell Biology, 2006, 16, 45-54.	7.9	408
198	Combined Methyltransferase/Histone Deacetylase Inhibition with 5-Azacitidine and MS-275 in Patients with MDS, CMMoL and AML: Clinical Response, Histone Acetylation and DNA Damage.. Blood, 2006, 108, 517-517.	1.4	17

#	Article	IF	Citations
199	Engineered Expression of JAK2V617F Drastically Changes the Response of Progenitor Cells to Erythropoietin and Partially Mimics the Polycythemia Expression Signature.. Blood, 2006, 108, 3597-3597.	1.4	0
200	A Comprehensive Genomic Approach Using Gain of Function and Loss of Function Cell Models and ChIP-on-Chip Technology Identifies Novel Promyelocytic Zinc Finger Protein Target Genes.. Blood, 2006, 108, 1407-1407.	1.4	0
201	Physical and Functional Association of PLZF with Histone Methyl Transferase and Histone Demethylase.. Blood, 2006, 108, 731-731.	1.4	0
202	The MMSET Protein Is Tightly Associated with Chromatin, Mediates Methylation of Specific Histone Residues and Forms a Complex with a Histone Demethylase.. Blood, 2006, 108, 730-730.	1.4	0
203	High Resolution SNP Arrays and Correlation with Expression Arrays Identify Novel Genomic Aberrations and Potential Disease Genes in Polycythemia Vera and Other Myeloproliferative Disorders.. Blood, 2006, 108, 359-359.	1.4	0
204	Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges. Current Opinion in Hematology, 2005, 12, 7-13.	2.5	32
205	Retinoid and growth factor receptor signaling in APL. Blood, 2005, 105, 1381-1382.	1.4	7
206	Over-expression of Flt3 induces NF-Î°B pathway and increases the expression of IL-6. Leukemia Research, 2005, 29, 893-899.	0.8	43
207	Synergistic activity of Sef and Sprouty proteins in regulating the expression ofGbx2 in the mid-hindbrain region. Genesis, 2005, 41, 110-115.	1.6	36
208	The BTB Domain Zinc Finger Proteins. , 2005, , 134-150.		2
209	Histone Acetyltransferase Activity of p300 Is Required for Transcriptional Repression by the Promyelocytic Leukemia Zinc Finger Protein. Molecular and Cellular Biology, 2005, 25, 5552-5566.	2.3	99
210	WT1 Induces Apoptosis through Transcriptional Regulation of the Proapoptotic Bcl-2 Family Member Bak. Cancer Research, 2005, 65, 8174-8182.	0.9	64
211	The Molecular Pathology of Acute Myeloid Leukemia. Hematology American Society of Hematology Education Program, 2005, 2005, 137-142.	2.5	40
212	The Theoretical Basis of Transcriptional Therapy of Cancer: Can It Be Put Into Practice?. Journal of Clinical Oncology, 2005, 23, 3957-3970.	1.6	31
213	Sprouty1 Is a Critical Regulator of GDNF/RET-Mediated Kidney Induction. Developmental Cell, 2005, 8, 229-239.	7.0	327
214	A Phase I-II Pilot Study of Divalproex Sodium Alone and in Combination with All-Trans-Retinoic Acid (ATRA) in Relapsed or Refractory Acute Myeloid Leukemia.. Blood, 2005, 106, 2799-2799.	1.4	1
215	The Multiple Myeloma SET Domain (MMSET) Protein Is a Histone H3 and H4 Methyltransferase with Properties of a Transcriptional Co-Repressor.. Blood, 2005, 106, 358-358.	1.4	0
216	The Transcriptional Profile of PV Displays Limited Similarity to EPO Stimulated Progenitor Cells: Evidence That JAK2 V617F Confers a Novel Program to Malignant Hematopoietic Stem Cells.. Blood, 2005, 106, 120-120.	1.4	1

#	Article	IF	Citations
217	WT1 Activates a Glomerular-Specific Enhancer Identified from the Human Nephrin Gene. Journal of the American Society of Nephrology: JASN, 2004, 15, 2851-2856.	6.1	94
218	Tyrosine Phosphorylation of Sprouty Proteins Regulates Their Ability to Inhibit Growth Factor Signaling: A Dual Feedback Loop. Molecular Biology of the Cell, 2004, 15, 2176-2188.	2.1	118
219	SPRY2 Is an Inhibitor of the Ras/Extracellular Signal-Regulated Kinase Pathway in Melanocytes and Melanoma Cells with Wild-Type BRAF but Not with the V599E Mutant. Cancer Research, 2004, 64, 5556-5559.	0.9	107
220	Despite WT1 binding sites in the promoter region of human and mouse nucleoporin glycoprotein 210, WT1 does not influence expression of GP210. Journal of Negative Results in BioMedicine, 2004, 3, 7.	1.4	3
221	Flt3 mutation activates p21WAF1/CIP1 gene expression through the action of STAT5. Biochemical and Biophysical Research Communications, 2004, 316, 85-92.	2.1	35
222	CTNNB1 Mutations and Overexpression of Wnt/Î²-Catenin Target Genes in WT1-Mutant Wilms' Tumors. American Journal of Pathology, 2004, 165, 1943-1953.	3.8	130
223	Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nature Medicine, 2004, 10, 1329-1335.	30.7	272
224	ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein. Blood, 2004, 103, 1454-1463.	1.4	70
225	The Flt3 internal tandem duplication mutant inhibits the function of transcriptional repressors by blocking interactions with SMRT. Blood, 2004, 103, 4650-4658.	1.4	42
226	Specific Peptide Disruption of the Bcl-6 Repression Complex Reveals Its Transcriptional Mechanism of Action in Normal and Malignant B-Cells and Is a Novel Therapeutic Approach for Diffuse Large B-Cell Lymphoma.. Blood, 2004, 104, 5-5.	1.4	3
227	The Transcriptional Program of Polycythemia Vera Revelas Altered Expression of Multiple Putative Tumor Suppressor Genes.. Blood, 2004, 104, 796-796.	1.4	1
228	Both the Activity and Stability of the Transcriptional Repressor PLZF Are Modified by the Class III Histone Deacetylase SIRT1.. Blood, 2004, 104, 360-360.	1.4	0
229	Histone Acetyltransferase Activity of p300 Is Required for Transcriptional Repression by the Promyelocytic Leukemia Zinc Finger Protein.. Blood, 2004, 104, 359-359.	1.4	0
230	Over-Expression of Flt3 Induces the Expression of NFkB Target Genes, cIAP-1 and IL-6.. Blood, 2004, 104, 2051-2051.	1.4	14
231	Identification of Genes Affected during Myeloid Differentiation Induced by Valproic Acid and Retinoic Acid: The Choice of Array Pre-Processing and Normalization Algorithm Has a Critical Effect on Results.. Blood, 2004, 104, 4207-4207.	1.4	0
232	Histone deacetylase inhibitors in cancer therapy. Cancer Cell, 2003, 4, 13-18.	16.8	451
233	Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nature Genetics, 2003, 34, 148-150.	21.4	960
234	Molecular pathogenesis of acute promyelocytic leukaemia and APL variants. Best Practice and Research in Clinical Haematology, 2003, 16, 387-408.	1.7	44

#	Article	IF	Citations
235	Mechanism of SMRT Corepressor Recruitment by the BCL6 BTB Domain. Molecular Cell, 2003, 12, 1551-1564.	9.7	251
236	Aberrant Eukaryotic Translation Initiation Factor 4E-Dependent mRNA Transport Impedes Hematopoietic Differentiation and Contributes to Leukemogenesis. Molecular and Cellular Biology, 2003, 23, 8992-9002.	2.3	198
237	The Receptor Tyrosine Kinase Regulator Sprouty1 Is a Target of the Tumor Suppressor WT1 and Important for Kidney Development. Journal of Biological Chemistry, 2003, 278, 41420-41430.	3.4	72
238	Growth Suppression by Acute PromyelocyticLeukemia-Associated Protein PLZF Is Mediated by Repression ofc-mycExpression. Molecular and Cellular Biology, 2003, 23, 9375-9388.	2.3	120
239	BRCA1 Augments Transcription by the NF-ÎºB Transcription Factor by Binding to the Rel Domain of the p65/RelA Subunit. Journal of Biological Chemistry, 2003, 278, 26333-26341.	3.4	67
240	Two molecular subgroups of Wilms' tumors with or without WT1 mutations. Clinical Cancer Research, 2003, 9, 2005-14.	7.0	49
241	Critical Residues within the BTB Domain of PLZF and Bcl-6 Modulate Interaction with Corepressors. Molecular and Cellular Biology, 2002, 22, 1804-1818.	2.3	200
242	The Effects of the Fanconi Anemia Zinc Finger (FAZF) on Cell Cycle, Apoptosis, and Proliferation Are Differentiation Stage-specific. Journal of Biological Chemistry, 2002, 277, 26327-26334.	3.4	33
243	The LIM-only Protein DRAL/FHL2 Interacts with and Is a Corepressor for the Promyelocytic Leukemia Zinc Finger Protein. Journal of Biological Chemistry, 2002, 277, 37045-37053.	3.4	67
244	Histone deacetylases as therapeutic targets in hematologic malignancies. Current Opinion in Hematology, 2002, 9, 322-332.	2.5	101
245	The human promyelocytic leukemia zinc finger gene is regulated by the Evi-1 oncoprotein and a novel guanine-rich site binding protein. Leukemia, 2002, 16, 1755-1762.	7.2	29
246	PLZF induces megakaryocytic development, activates Tpo receptor expression and interacts with GATA1 protein. Oncogene, 2002, 21, 6669-6679.	5.9	46
247	Sprouty Proteins, A New Family of Receptor Tyrosine Kinase Inhibitors. Current Genomics, 2002, 3, 285-293.	1.6	1
248	The HIV-1 transactivator protein Tat is a potent inducer of the human DNA repair enzyme Î²-polymerase. Aids, 2001, 15, 433-440.	2.2	16
249	The acute promyelocytic leukemiaâ€"associated protein, promyelocytic leukemia zinc finger, regulates 1,25-dihydroxyvitamin D3â€"induced monocytic differentiation of U937 cells through a physical interaction with vitamin D3receptor. Blood, 2001, 98, 3290-3300.	1.4	52
250	AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML. Oncogene, 2001, 20, 5660-5679.	5.9	168
251	Translocations of the RARÎ± gene in acute promyelocytic leukemia. Oncogene, 2001, 20, 7186-7203.	5.9	206
252	Mammalian Sprouty Proteins Inhibit Cell Growth and Differentiation by Preventing Ras Activation. Journal of Biological Chemistry, 2001, 276, 46460-46468.	3.4	225

#	Article	IF	Citations
253	Cloning and Characterization of a Novel Mouse AP-2 Transcription Factor, Ap-2Î´, with Unique DNA Binding and Transactivation Properties. Journal of Biological Chemistry, 2001, 276, 40755-40760.	3.4	133
254	Targeting aberrant transcriptional repression in leukemia: a therapeutic reality?. Journal of Clinical Investigation, 2001, 108, 1277-1278.	8.2	5
255	Targeting aberrant transcriptional repression in leukemia: a therapeutic reality?. Journal of Clinical Investigation, 2001, 108, 1277-1278.	8.2	0
256	AML-1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein. Blood, 2000, 96, 3939-3947.	1.4	59
257	E-cadherin Is a WT1 Target Gene. Journal of Biological Chemistry, 2000, 275, 10943-10953.	3.4	112
258	BRCA1 Physically and Functionally Interacts with ATF1. Journal of Biological Chemistry, 2000, 275, 36230-36237.	3.4	55
259	The ETO Protein Disrupted in t(8;21)-Associated Acute Myeloid Leukemia Is a Corepressor for the Promyelocytic Leukemia Zinc Finger Protein. Molecular and Cellular Biology, 2000, 20, 2075-2086.	2.3	134
260	In-Depth Mutational Analysis of the Promyelocytic Leukemia Zinc Finger BTB/POZ Domain Reveals Motifs and Residues Required for Biological and Transcriptional Functions. Molecular and Cellular Biology, 2000, 20, 6550-6567.	2.3	167
261	AML-1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein. Blood, 2000, 96, 3939-3947.	1.4	9
262	In-Depth Mutational Analysis of the Promyelocytic Leukemia Zinc Finger BTB/POZ Domain Reveals Motifs and Residues Required for Biological and Transcriptional Functions. Molecular and Cellular Biology, 2000, 20, 6550-6567.	2.3	13
263	Deconstructing a Disease: RARîœ€, Its Fusion Partners, and Their Roles in the Pathogenesis of Acute Promyelocytic Leukemia. Blood, 1999, 93, 3167-3215.	1.4	990
264	A Novel BTB/POZ Transcriptional Repressor Protein Interacts With the Fanconi Anemia Group C Protein and PLZF. Blood, 1999, 94, 3737-3747.	1.4	129
265	The promyelocytic leukemia zinc finger (PLZF) protein binds DNA in a high molecular weight complex associated with cdc2 kinase. Nucleic Acids Research, 1999, 27, 4106-4113.	14.5	57
266	Genomic sequence, structural organization, molecular evolution, and aberrant rearrangement of promyelocytic leukemia zinc finger gene. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 11422-11427.	7.1	47
267	Tumor-associated WT1 Missense Mutants Indicate That Transcriptional Activation by WT1 Is Critical for Growth Control. Journal of Biological Chemistry, 1999, 274, 13258-13263.	3.4	29
268	Identification of novel chromosomal rearrangements in acute myelogenous leukemia involving loci on chromosome 2p23, 15q22 and 17q21. Leukemia, 1999, 13, 1534-1538.	7.2	18
269	WT1 expression induces features of renal epithelial differentiation in mesenchymal fibroblasts. Oncogene, 1999, 18, 417-427.	5.9	47
270	Deregulation of NPM and PLZF in a variant t(5;17) case of acute promyelocytic leukemia. Oncogene, 1999, 18, 633-641.	5.9	59

#	Article	IF	Citations
271	Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARÎ± fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient. Oncogene, 1999, 18, 1113-1118.	5.9	97
272	Leukemia translocation protein PLZF inhibits cell growth and expression of cyclin A. Oncogene, 1999, 18, 925-934.	5.9	177
273	Genomic structure of the human PLZF gene. Gene, 1999, 236, 21-24.	2.2	6
274	A Novel BTB/POZ Transcriptional Repressor Protein Interacts With the Fanconi Anemia Group C Protein and PLZF. Blood, 1999, 94, 3737-3747.	1.4	9
275	The Promyelocytic Leukemia Zinc Finger Protein Affects Myeloid Cell Growth, Differentiation, and Apoptosis. Molecular and Cellular Biology, 1998, 18, 5533-5545.	2.3	164
276	Sequence-specific DNA Binding and Transcriptional Regulation by the Promyelocytic Leukemia Zinc Finger Protein. Journal of Biological Chemistry, 1997, 272, 22447-22455.	3.4	161
277	Two Evolutionarily Conserved Repression Domains in the <i>Drosophila KrÃ¼ppel</i> Protein Differ in Activator Specificity. Molecular and Cellular Biology, 1997, 17, 4820-4829.	2.3	26
278	Leukemia-associated retinoic acid receptor Â fusion partners, PML and PLZF, heterodimerize and colocalize to nuclear bodies. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 10255-10260.	7.1	115
279	Two N-Terminal Self-Association Domains Are Required for the Dominant Negative Transcriptional Activity of WT1 Denys-Drash Mutant Proteins. Biochemical and Biophysical Research Communications, 1997, 233, 723-728.	2.1	38
280	Transcription Factors, Normal Myeloid Development, and Leukemia. Blood, 1997, 90, 489-519.	1.4	684
281	Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiPl. Nature, 1997, 389, 187-190.	27.8	509
282	Transcription Factors, Normal Myeloid Development, and Leukemia. Blood, 1997, 90, 489-519.	1.4	183
283	Amino-terminal protein-protein interaction motif (POZ-domain) is responsible for activities of the promyelocytic leukemia zinc finger-retinoic acid receptor-alpha fusion protein.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 3624-3629.	7.1	169
284	The WT1 Wilms' tumor suppressor gene: How much do we really know?. Biochimica Et Biophysica Acta: Reviews on Cancer, 1996, 1287, 1-28.	7.4	72
285	Expression of the zinc-finger gene PLZF at rhombomere boundaries in the vertebrate hindbrain.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 2249-2253.	7.1	118
286	The Transcriptional Effect of WT1 Is Modulated by Choice of Expression Vector. Journal of Biological Chemistry, 1995, 270, 29976-29982.	3.4	44
287	WT1-mediated Transcriptional Activation Is Inhibited by Dominant Negative Mutant Proteins. Journal of Biological Chemistry, 1995, 270, 10878-10884.	3.4	148
288	Phase IV trial of daily oral etoposide in the treatment of advanced soft-tissue sarcoma. Cancer Chemotherapy and Pharmacology, 1994, 34, 79-80.	2.3	13

#	Article	IF	Citations
289	Phase IV trial of daily oral etoposide in the treatment of advanced soft-tissue sarcoma. Cancer Chemotherapy and Pharmacology, 1994, 34, 79-80.	2.3	1
290	NGFIA (EGR1) Contains Transcription Activating Domains in Both the Amino Terminal and Carboxyl Terminal Regions of the Protein. Biochemical and Biophysical Research Communications, 1993, 194, 425-431.	2.1	8
291	Selective repression of transcriptional activators at a distance by the Drosophila KrÃ¼ppel protein. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 11361-11365.	7.1	47
292	Phase II trial of trimetrexate in patients with advanced soft-tissue sarcoma. Cancer Chemotherapy and Pharmacology, 1991, 28, 223-225.	2.3	12
293	Drosophila KrÃ¼ppel protein is a transcriptional represser. Nature, 1990, 346, 76-79.	27.8	250
294	Treatment of low-grade and intermediate-grade lymphoma with intensive combination chemotherapy results in long-term, disease-free survival. Cancer, 1990, 66, 632-639.	4.1	12
295	Elevated CK-MB with normal total creatine kinase in suspected myocardial infarction: Associated clinical findings and early prognosis. American Heart Journal, 1986, 111, 1041-1047.	2.7	49
296	E2A and the Development of B and T Lymphocytes. , 0, , 255-270.		0
297	The Role of RARÎ± and Its Fusion Partners in Acute Promyelocytic Leukemia. , 0, , 325-378.		0
298	t(8;21) AML and the AML1/ETO Fusion Gene: From Clinical Syndrome to Paradigm for the Molecular Basis of Acute Leukemia. , 0, , 409-424.		1
299	MLL in Normal and Malignant Hematopoiesis. , 0, , 447-463.		0
300	Transcription Factors Implicated in Hematopoiesis: In Vivo Studies. , 0, , 571-591.		0
301	The Roles of the c-myc and c-myb Oncogenes in Hematopoiesis and Leukemogenesis. , 0, , 519-549.		1
302	The Role of GATA-1 and FOG in Erythroid and Megakaryocytic Differentiation. , 0, , 1-12.		1
303	The Role of Pax5 (BSAP) in Early and Late B-Cell Development. , 0, , 217-228.		0
304	EVI1 Rearrangements in Malignant Hematopoiesis. , 0, , 393-408.		0
305	TEL/ETV6 Gene Rearrangements in Human Leukemias. , 0, , 425-445.		0
306	Chromosomal Translocations Associated with Disruption of Transcriptional Regulators in Leukemia and Lymphoma. , 0, , 593-597.		0

#	Article	IF	Citations
307	RUNX1(AML1) and CBFB: Genes Required for the Development of all Definitive Hematopoietic Lineages. , 0, , 85-102.		1
308	PU.1 and the Development of the Myeloid Lineage. , 0, , 103-115.		0
309	The Role of Retinoic Acid Receptors in Myeloid Differentiation. , 0, , 149-161.		0
310	Homeobox Gene Networks and the Regulation of Hematopoiesis. , 0, , 133-148.		0
311	The Role of Ikaros Family Genes in Lymphocyte Differentiation and Proliferation. , 0, , 181-199.		0
312	The Acetyltransferases CBP and p300: Molecular Integrators of Hematopoietic Transcription Involved in Chromosomal Translocations. , 0, , 497-517.		0
313	The LMO2 Master Gene; Its Role as a Transcription Regulator Determining Cell Fate in Leukemogenesis and in Hematopoiesis. , 0, , 483-495.		0
314	EKLF and the Development of the Erythroid Lineage. , 0, , 71-84.		11
315	The Role of Early B-cell Factor in B-lymphocyte Development. , 0, , 313-324.		0
316	Janus Kinases and STAT Family Transcription Factors: Their Role in the Function and Development of Lymphoid Cells. , 0, , 229-254.		0
317	NF-Î°B in Cell Life and Death. , 0, , 551-570.		0
318	The Role of Octamer Factors and Their Coactivators in the Lymphoid System. , 0, , 291-311.		0
319	Role of the TAL1/SCL Transcription Factor in Normal and Leukemic Hematopoiesis. , 0, , 51-70.		0
320	CCAAT/Enhancer-Binding Proteins in Myeloid Cells. , 0, , 117-131.		0
321	Regulation of Megakaryocyte and Erythroid Differentiation by NF-E2. , 0, , 13-29.		0
322	Transcriptional Targets of the Vitamin D3 Receptor During Myeloid Cell Differentiation. , 0, , 163-180.		1
323	Transcription Factors Involved in Lineage-specific Gene Expression During Megakaryopoiesis. , 0, , 31-49.		0
324	Coactivators and Leukemia: The Acetylation Connection with Translocations Involving CBP, p300, TIF2, MOZ, and MLL. , 0, , 465-481.		0

#	Article	IF	Citations
325	The Leukemogenic Function of the inv(16) Fusion Gene CBFB-MYH11. , 0, , 379-391.		0
326	The molecular basis of acute myeloid leukemia. , 0, , 751-768.		0
327	Sprouty 3. The AFCS-nature Molecule Pages, 0, , .	0.2	0
328	Sprouty 4. The AFCS-nature Molecule Pages, 0, , .	0.2	0
329	Sprouty 1. The AFCS-nature Molecule Pages, 0, , .	0.2	0
330	The Role of BCL-6 in Normal Lymphoid System and non-Hodgkin's Lymphomas. , 0, , 271-289.		1
331	The Role of PU.1 in B-lymphocyte Development and Function. , 0, , 201-216.		0